论文部分内容阅读
目的 研究单纯注射胶体32P和先注入聚合白蛋白（MAA），再注射胶体32P两种不同给药方法的32P体内分布情况，探讨瘤内注射MAA和胶体32P治疗肝癌的疗效与副作用。 方法 在Bal b/c 小鼠右侧胸前皮下接种H22肝癌细胞，10d后长出直径约1cm的肿瘤，将其随机分为2组，第1组只注射胶体32P 1.85MBq；第2组先注入1×105颗粒MAA，再注入胶体32P 1.85MBq，注射后30min、24h、48h、8d和16d分别测定肿瘤组织、外周血液和心、肝、脾、肾、骨髓的放射性；第16天和1个月时对肿瘤组织作病理切片，观察治疗效果。临床上B超引导下将MAA和胶体32P依次瘤内注射治疗肝癌30例，观察治疗前后临床症状、肿块大小、AFP水平、心肝肾功能、外周血象和免疫指标。 结果 胶体32P内照射可使肿瘤组织坏死、纤维化。预先注射MAA，MAA可以有效阻止32P的全身扩散，使胶体32P长时间滞留在肿瘤内。临床应用发现该方法可使肿块缩小，平均缩小率53.25%，血清AFP水平下降，临床症状改善，1、2、3年生存率分别为90%、76.67%、43.33%，无心、肝、肾损害和骨髓抑制等副作用。 结论 瘤内注射MAA和胶体32P是一种简单、安全、有效的治疗肝癌的新方法。
OBJECTIVE: To study the in vivo distribution of 32P administered by injection of colloidal 32P, injection of polyaminated albumin (MAA), and injection of colloidal 32P, and to investigate the efficacy and side effects of intratumoral injection of MAA and colloidal 32P in the treatment of liver cancer. Methods H22 hepatocarcinoma cells were subcutaneously inoculated into the right chest of Bal b/c mice. After 10 days, tumors with a diameter of about 1 cm were grown. They were randomly divided into two groups. Group 1 received only colloidal 32P 1.85 MBq; Inject 1 × 105 particles of MAA, and then inject colloidal 32P 1.85MBq, and measure the tumor tissue, peripheral blood, and radioactivity of heart, liver, spleen, kidney, and bone marrow at 30 min, 24h, 48h, 8d, and 16d after injection; Day 16 and 1 At the time of month, the tumor tissue was sectioned for pathology and the therapeutic effect was observed. Under the guidance of B ultrasound, MAA and colloidal 32P were injected intratumorally to treat 30 cases of liver cancer. The clinical symptoms, mass size, AFP level, heart and liver function, peripheral blood and immune parameters before and after treatment were observed. Results The colloidal 32P irradiation could make tumor tissue necrosis and fibrosis. Pre-injection of MAA, MAA can effectively prevent the systemic spread of 32P, so that colloidal 32P stay in the tumor for a long time. Clinical application found that this method can shrink the mass, the average reduction rate of 53.25%, serum AFP levels decreased, clinical symptoms improved, 1,2,3-year survival rates were 90%, 76.67%, 43.33%, no heart, liver and kidney damage Side effects such as myelosuppression. Conclusion Intratumoral injection of MAA and colloidal 32P is a simple, safe and effective method for the treatment of liver cancer.